Thailand is preparing to produce locally produced Molnupiravir, an antiviral medication for COVID-19, available this week, as the government simultaneously adjusts its emergency care protocols for the virus.
The move comes as medical professionals continue to evaluate the efficacy of antiviral treatments like Molnupiravir and Ritonavir-boosted Nirmatrelvir in real-world settings. A recent phase 2, randomized, controlled trial – PLATCOV – investigated the antiviral efficacy of Molnupiravir versus Ritonavir-boosted Nirmatrelvir in patients experiencing early symptomatic COVID-19, the results of which were published in The Lancet.
The Thai initiative aims to bolster the country’s response to COVID-19, though data regarding the effectiveness of Molnupiravir and similar agents like Remdesivir, remains limited, particularly within the Thai healthcare system. The Bangkok Post reported that the government has outlined changes to the criteria for accessing emergency COVID-19 care, suggesting a recalibration of resources as the pandemic evolves.
Recent reports highlight the potential impact of antiviral pills on reducing hospitalization rates related to COVID-19, with some describing them as “unquestionably a game changer.” Though, the specifics of how these changes to emergency care access will affect patient outcomes in Thailand remain to be seen.
